Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
PFE
Pfizer
$25.38
Chart
$23.46 (+8.18%)
$22.14 (+14.63%)
$26.24 (-3.28%)
$30.72 (-17.38%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
PFE
Pfizer
Current Price
$25.38
Buy
Login to view Pfizer (PFE) recommendation from the last 90 days from financial news and social media.
Chart
$23.46 (+8.18%)
$22.14 (+14.63%)
$26.24 (-3.28%)
$30.72 (-17.38%)
PFE Latest Analysis
Wall Streets Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields. During times of turbulence and uncertainty in the markets many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga'.s extensive database of
Mon Jul 21, 2025
Bristol‑Myers Squibb Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off. The)) alliance annoEliquis is a blood-thinning medication that reduces blood clotting and prevents strokes.In May 2024 Pfizer said it is on the success of itsCOVID-19vaccine rollout by introducing a direct-to-consumer medicines platform under the brand Pfizer for All.In August 2024 with The move as reflected in a recent trademark application aims to provide medical information mail-order pharmacy services and telehe
Thu Jul 17, 2025
Bristol Myers Squibb Pfizer to sell blockbuster blood thinner Eliquis at 40% discount. The companies new effort would bypass traditional middlemen to cut the drugs monthly cost from a list price of around $606 to $346.
Thu Jul 17, 2025
Bristol-Myers and Pfizer to offer 40% discount on blockbuster blood thinner Eliquis.
Thu Jul 17, 2025
Bristol-Myers and Pfizer to offer 40% discount on blockbuster blood thinner Eliquis - report.
Thu Jul 17, 2025
Pfizer (PFE) Shares Cross 7% Yield Mark. Looking at the universe of stocks we cover at Dividend Channel in trading on Tuesday shares of Pfizer Inc (Symbol: PFE) were yielding above the 7% mark based on its quarterly dividend (annualized to $1.72) with the stock changing hands as low as $24.55 on the day. Dividends
Tue Jul 15, 2025
Recent Report Shows That Sen. Ron L Wyden Sold Up to $15K Worth of Pfizer Stock. On July 2 2025 it was reported that Senator Ron L Wyden executed a sale of Pfizer (NYSE:) stock valued between $1001 and $15000. The transaction recorded in the July filing was made on June 3 2025.At the time of writing Pfizer shares are trading up 0.33% at $25.4.In the past three years Ron L Wyden made 20 stock trades totaling more than $596 thousand. The largest trades involved stocks like PayPal Holdings and Unit
Thu Jul 3, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings